OncoMatch/Clinical Trials/NCT07479732
Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
Is NCT07479732 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Liposomal Irinotecan and Apatinib in arm1 for osteosarcoma.
Treatment: Liposomal Irinotecan · Apatinib in arm1 — In advanced osteosarcoma where traditional chemotherapy has failed, the multi-targeted tyrosine kinase inhibitor apatinib has become a mainstream systemic treatment option in China. However, for patients with a high tumor burden or extra-pulmonary lesions, these drugs are prone to secondary resistance, necessitating combination with chemotherapy for more effective comprehensive control. Liposomal irinotecan, a newly approved topoisomerase inhibitor, exhibits lower toxicity compared to traditional irinotecan and is one of the second-line chemotherapy agents for osteosarcoma, making it a suitable candidate for combination therapy with apatinib. The primary objective of this study is to determine the optimal regimen of apatinib combined with liposomal irinotecan injection, while the secondary objective is to evaluate the safety and efficacy of this combination in patients with refractory osteosarcoma who have progressed after second-line chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Osteosarcoma
Disease stage
Metastatic disease required
Osteosarcoma Metastatic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: cytotoxic chemotherapy — first-line and second-line
Disease progression after standard, adequate first-line and second-line chemotherapy regimens for osteosarcoma, or progression within 6 months of stopping such therapy.
Cannot have received: VEGFR inhibitor (apatinib)
Prior treatment with apatinib.
Cannot have received: topoisomerase inhibitor (irinotecan)
Prior use of irinotecan or other analogues of topoisomerase inhibitors.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify